FR09C0065I1 - - Google Patents

Info

Publication number: FR09C0065I1
Authority: FR; France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-27

Filing date

2009-12-15

Publication date

2010-01-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10773597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0065(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-15 Application filed filed Critical

2010-01-22 Publication of FR09C0065I1 publication Critical patent/FR09C0065I1/fr

2014-03-28 Application granted granted Critical

2014-03-28 Publication of FR09C0065I2 publication Critical patent/FR09C0065I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

FR09C0065C 1995-04-27 2009-12-15 Derives de quinazoline Active FR09C0065I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9508538.7A GB9508538D0 (en)	1995-04-27	1995-04-27	Quinazoline derivatives
PCT/GB1996/000961 WO1996033980A1 (en)	1995-04-27	1996-04-23	Quinazoline derivatives

Publications (2)

Publication Number	Publication Date
FR09C0065I1 true FR09C0065I1 (ja)	2010-01-22
FR09C0065I2 FR09C0065I2 (fr)	2014-03-28

Family

ID=10773597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR09C0065C Active FR09C0065I2 (fr)	1995-04-27	2009-12-15	Derives de quinazoline

Country Status (39)

Country	Link
US (1)	US5770599A (ja)
EP (1)	EP0823900B1 (ja)
JP (1)	JP3040486B2 (ja)
KR (1)	KR100296656B1 (ja)
CN (1)	CN1100046C (ja)
AR (1)	AR003944A1 (ja)
AT (1)	ATE198329T1 (ja)
AU (1)	AU699163B2 (ja)
BG (1)	BG62730B1 (ja)
BR (1)	BRPI9608082B8 (ja)
CA (1)	CA2215732C (ja)
CZ (1)	CZ288489B6 (ja)
DE (2)	DE69611361T2 (ja)
DK (1)	DK0823900T3 (ja)
EE (1)	EE03482B1 (ja)
EG (1)	EG24134A (ja)
ES (1)	ES2153098T3 (ja)
FR (1)	FR09C0065I2 (ja)
GB (1)	GB9508538D0 (ja)
GR (1)	GR3035211T3 (ja)
HK (1)	HK1005371A1 (ja)
HR (1)	HRP960204B1 (ja)
HU (1)	HU223313B1 (ja)
IL (1)	IL118045A (ja)
LU (1)	LU91631I2 (ja)
MY (1)	MY114425A (ja)
NL (1)	NL300429I1 (ja)
NO (2)	NO309472B1 (ja)
NZ (1)	NZ305444A (ja)
PL (1)	PL189182B1 (ja)
PT (1)	PT823900E (ja)
RO (1)	RO117849B1 (ja)
RU (1)	RU2153495C2 (ja)
SI (1)	SI0823900T1 (ja)
SK (1)	SK282236B6 (ja)
TW (1)	TW436486B (ja)
UA (1)	UA52602C2 (ja)
WO (1)	WO1996033980A1 (ja)
ZA (1)	ZA963358B (ja)

Families Citing this family (724)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6811779B2 (en)	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
TW321649B (ja) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
JPH11507329A (ja) *	1995-04-27	1999-06-29	ゼネカリミテッド	キナゾリン誘導体
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
US7060808B1 (en) *	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
ATE237596T1 (de)	1996-02-13	2003-05-15	Astrazeneca Ab	Chinazolinderivate und deren verwendung als vegf hemmer
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
GB9603097D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
PT885198E (pt)	1996-03-05	2002-06-28	Astrazeneca Ab	Derivados de 4-anilinoquinazolina
EA001595B1 (ru)	1996-04-12	2001-06-25	Варнер-Ламберт Компани	Необратимые ингибиторы тирозинкиназ
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
AU737092B2 (en) *	1997-08-15	2001-08-09	Cephalon, Inc.	Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
US6294532B1 (en)	1997-08-22	2001-09-25	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
US20030224001A1 (en) *	1998-03-19	2003-12-04	Goldstein Neil I.	Antibody and antibody fragments for inhibiting the growth of tumors
US6864227B1 (en)	1998-04-13	2005-03-08	California Institute Of Technology	Artery-and vein-specific proteins and uses therefor
US6887674B1 (en)	1998-04-13	2005-05-03	California Institute Of Technology	Artery- and vein-specific proteins and uses therefor
ZA200007412B (en) *	1998-05-15	2002-03-12	Imclone Systems Inc	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7354894B2 (en) *	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
RS50273B (sr)	1998-08-18	2009-07-15	The Regents Of The Univeristy Of California,	Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima
DE69924500T2 (de)	1998-08-21	2006-02-09	Parker Hughes Institute, St. Paul	Chinazolinderivate
US6288082B1 (en)	1998-09-29	2001-09-11	American Cyanamid Company	Substituted 3-cyanoquinolines
EP1117649A1 (en)	1998-09-29	2001-07-25	American Cyanamid Company	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
IL142921A0 (en) *	1998-11-20	2002-04-21	Genentech Inc	USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
EP2298746A1 (en)	1999-02-27	2011-03-23	Boehringer Ingelheim Pharma GmbH & Co. KG	4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911509A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
IL146480A0 (en) *	1999-05-14	2002-07-25	Imclone Systems Inc	Treatment of refractory human tumors with epidermal growth factor receptor antagonists
CA2375259C (en)	1999-06-21	2009-04-28	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6432979B1 (en)	1999-08-12	2002-08-13	American Cyanamid Company	Method of treating or inhibiting colonic polyps and colorectal cancer
GB9925958D0 (en) *	1999-11-02	1999-12-29	Bundred Nigel J	Therapeutic use
DK1244647T3 (da)	1999-11-05	2006-09-25	Astrazeneca Ab	Quinzolinderivater som VIGF-inhibitorer
US20020002169A1 (en)	1999-12-08	2002-01-03	Griffin John H.	Protein kinase inhibitors
GB0002952D0 (en) *	2000-02-09	2000-03-29	Pharma Mar Sa	Process for producing kahalalide F compounds
GB0007371D0 (en)	2000-03-28	2000-05-17	Astrazeneca Uk Ltd	Chemical compounds
GB0008368D0 (en) *	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
CN1240688C (zh)	2000-04-07	2006-02-08	阿斯特拉曾尼卡有限公司	喹唑啉化合物
EP1170011A1 (en) *	2000-07-06	2002-01-09	Boehringer Ingelheim International GmbH	Novel use of inhibitors of the epidermal growth factor receptor
WO2002011677A2 (en) *	2000-08-09	2002-02-14	Imclone Systems Incorporated	Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
DE10042059A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en)	2000-08-26	2004-05-25	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6656946B2 (en)	2000-08-26	2003-12-02	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en)	2000-08-26	2002-06-11	Boehringer Ingelheim Pharma Kg	Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6617329B2 (en)	2000-08-26	2003-09-09	Boehringer Ingelheim Pharma Kg	Aminoquinazolines and their use as medicaments
AU2001292137A1 (en) *	2000-10-13	2002-04-22	Astrazeneca Ab	Quinazoline derivatives
RU2264389C3 (ru)	2000-10-20	2018-06-01	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
DE10206505A1 (de) *	2002-02-16	2003-08-28	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
US7776315B2 (en)	2000-10-31	2010-08-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and additional active ingredients
AU2002217999A1 (en)	2000-11-01	2002-05-15	Cor Therapeutics, Inc.	Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
EP3406249A1 (en)	2001-02-19	2018-11-28	Novartis AG	Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor
US20080008704A1 (en) *	2001-03-16	2008-01-10	Mark Rubin	Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
DE60219617T2 (de)	2001-05-16	2008-01-03	Novartis Ag	Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
WO2003000188A2 (en)	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Novel quinazolines and uses thereof
DE10204462A1 (de) *	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1481971B1 (en)	2002-02-06	2011-11-16	Ube Industries, Ltd.	Process for producing 4-aminoquinazoline compound
GB0204392D0 (en) *	2002-02-26	2002-04-10	Astrazeneca Ab	Pharmaceutical compound
DE60332322D1 (de) *	2002-02-26	2010-06-10	Astrazeneca Ab	Neue kristalline formen der krebsbekämpfenden verbindung zd1839
PL208114B1 (pl) *	2002-02-26	2011-03-31	Astrazeneca Ab	Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
TW200813014A (en) *	2002-03-28	2008-03-16	Astrazeneca Ab	Quinazoline derivatives
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60311788T2 (de) *	2002-04-16	2007-11-22	Astrazeneca Ab	Kombinationstherapie zur behandlung von krebs
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
DK1505959T3 (da)	2002-05-16	2009-02-23	Novartis Ag	Anvendelse af EDG-receptorbindingsmidler ved cancer
US20040048887A1 (en) *	2002-07-09	2004-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
ES2376165T3 (es)	2002-07-15	2012-03-09	F. Hoffmann-La Roche Ag	Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
AU2003249212C1 (en)	2002-07-15	2011-10-27	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
GB0221245D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Chemical process
DK1553975T3 (da)	2002-09-27	2012-05-07	Xencor Inc	Optimerede Fc-varianter og fremgangsmåder til generering heraf.
GB0223854D0 (en) *	2002-10-12	2002-11-20	Astrazeneca Ab	Therapeutic treatment
GB0304367D0 (en) *	2003-02-26	2003-04-02	Pharma Mar Sau	Methods for treating psoriasis
EP1567506A4 (en)	2002-11-20	2007-06-20	Array Biopharma Inc	CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
JPWO2004060400A1 (ja) *	2003-01-06	2006-05-11	那波　宏之	上皮成長因子受容体を分子標的とする抗精神病薬
AU2004205642C1 (en)	2003-01-14	2012-01-12	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0302882D0 (en) *	2003-02-07	2003-03-12	Univ Cardiff	Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
US7223749B2 (en)	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
EP1604665B1 (en)	2003-03-10	2011-05-11	Eisai R&D Management Co., Ltd.	C-kit kinase inhibitor
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7585967B2 (en) *	2003-03-12	2009-09-08	Vasgene Therapeutics, Inc.	Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP1622941A2 (en) *	2003-03-20	2006-02-08	ImClone Systems Incorporated	Method of producing an antibody to epidermal growth factor receptor
GB0309850D0 (en)	2003-04-30	2003-06-04	Astrazeneca Ab	Quinazoline derivatives
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
EP2644195A1 (en)	2003-05-19	2013-10-02	Irm Llc	Immunosuppressant Compounds and Compositions
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
PA8603801A1 (es)	2003-05-27	2004-12-16	Janssen Pharmaceutica Nv	Derivados de la quinazolina
CA2527680A1 (en)	2003-05-30	2005-06-02	Astrazeneca Uk Limited	Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
DE10326186A1 (de) *	2003-06-06	2004-12-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2005001053A2 (en)	2003-06-09	2005-01-06	Samuel Waksal	Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
ES2523837T3 (es)	2003-07-18	2014-12-01	Amgen Inc.	Agentes de unión específica al factor de crecimiento de hepatocitos
GB0317663D0 (en) *	2003-07-29	2003-09-03	Astrazeneca Ab	Pharmaceutical composition
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
WO2005012290A1 (en) *	2003-07-29	2005-02-10	Astrazeneca Ab	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0320793D0 (en) *	2003-09-05	2003-10-08	Astrazeneca Ab	Chemical process
GB0321066D0 (en) *	2003-09-09	2003-10-08	Pharma Mar Sau	New antitumoral compounds
AU2004272345A1 (en) *	2003-09-16	2005-03-24	Astrazeneca Ab	Quinazoline derivatives
MXPA06002964A (es)	2003-09-16	2006-06-14	Astrazeneca Ab	Derivados de quinazolina como inhibidores de cinasa de tirosina.
ATE352550T1 (de) *	2003-09-19	2007-02-15	Astrazeneca Ab	Chinazolinderivate
DE602004004811T2 (de) *	2003-09-19	2007-11-22	Astrazeneca Ab	Chinazolinderivate
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
AU2004276055A1 (en) *	2003-09-25	2005-04-07	Astrazeneca Ab	Quinazoline derivatives
SI2392564T1 (sl) *	2003-09-26	2014-02-28	Exelixis, Inc.	c-Met modulatorji in postopki uporabe
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
PT2489364E (pt)	2003-11-06	2015-04-16	Seattle Genetics Inc	Compostos de monometilvalina conjugados com anticorpos
CN100450998C (zh)	2003-11-11	2009-01-14	卫材R&D管理有限公司	脲衍生物的制备方法
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
EP1697384B1 (en)	2003-12-18	2008-04-02	Janssen Pharmaceutica N.V.	Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
US20050221501A1 (en) *	2003-12-24	2005-10-06	Arnot Kate I	Dissolution method
WO2005070909A1 (en) *	2004-01-22	2005-08-04	Natco Pharma Limited	An improved process for the preparation of gefitinib
WO2005075439A1 (en)	2004-02-03	2005-08-18	Astrazeneca Ab	Quinazoline derivatives
ATE492564T1 (de)	2004-03-12	2011-01-15	Vasgene Therapeutics Inc	Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
WO2005090406A2 (en) *	2004-03-12	2005-09-29	Vasgene Therapeutics, Inc.	Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
PT1735348E (pt)	2004-03-19	2012-07-24	Imclone Llc	Anticorpo anti-receptor do factor de crescimento humano
WO2005097137A2 (en) *	2004-03-31	2005-10-20	The Scripps Research Institute	Advanced quinazoline based protein kinase inhibitors
KR101368446B1 (ko)	2004-03-31	2014-02-28	다나-파버 캔서 인스티튜트 인크.	암에 걸린 인간 환자의 표피성장인자 수용체 표적 치료의 유효 가능성 결정 방법, 키트, 핵산 프로브, 프라이머쌍 및 단리된 단백질
CN1964970B (zh)	2004-04-07	2011-08-03	诺瓦提斯公司	Iap的抑制剂
BRPI0510717B8 (pt) *	2004-05-06	2021-05-25	Bioresponse Llc	uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
BRPI0510604B8 (pt)	2004-05-06	2021-05-25	Warner Lambert Co	composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende
EP2286844A3 (en)	2004-06-01	2012-08-22	Genentech, Inc.	Antibody-drug conjugates and methods
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
CA2571421A1 (en)	2004-06-24	2006-01-05	Nicholas Valiante	Compounds for immunopotentiation
AU2005272993B2 (en)	2004-07-15	2010-02-11	Xencor, Inc.	Optimized Fc variants
WO2006030826A1 (ja)	2004-09-17	2006-03-23	Eisai R & D Management Co., Ltd.	医薬組成物
ES2529451T3 (es)	2004-09-23	2015-02-20	Vasgene Therapeutics, Inc.	Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral
ES2579805T3 (es)	2004-09-23	2016-08-16	Genentech, Inc.	Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
JP2008521900A (ja)	2004-11-30	2008-06-26	アムジエン・インコーポレーテツド	キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
NI200700147A (es)	2004-12-08	2019-05-10	Janssen Pharmaceutica Nv	Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) *	2004-12-08	2017-03-15	Janssen Pharmaceutica Nv	مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
WO2006064196A1 (en)	2004-12-14	2006-06-22	Astrazeneca Ab	Pyrazolopyrimidine compounds as antitumor agents
CA2593084C (en)	2004-12-30	2014-03-18	Bioresponse, Llc	Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
DOP2006000010A (es)	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
JP2008528486A (ja)	2005-01-21	2008-07-31	ジェネンテック・インコーポレーテッド	Ｈｅｒ抗体の一定投薬
US20080161251A1 (en)	2005-01-21	2008-07-03	Astex Therapeutics Limited	Pharmaceutical Compounds
GB0501999D0 (en) *	2005-02-01	2005-03-09	Sentinel Oncology Ltd	Pharmaceutical compounds
RU2405566C2 (ru)	2005-02-03	2010-12-10	Дзе Дженерал Хоспитал Корпорейшн	Способ лечения рака, устойчивого к гефитинибу
US20090155247A1 (en) *	2005-02-18	2009-06-18	Ashkenazi Avi J	Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) *	2005-02-18	2006-08-24	Genentech, Inc.	Methods of using death receptor agonists and EGFR inhibitors
RU2404806C2 (ru)	2005-02-23	2010-11-27	Дженентек, Инк.	Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
WO2006090413A1 (en) *	2005-02-23	2006-08-31	Natco Pharma Limited	Novel crystalline form of gefitinib and a process for its preparation
CA2599210A1 (en)	2005-02-26	2006-08-31	Astrazeneca Ab	Quinazoline derivatives as tyrosine kinase inhibitors
CA2599115A1 (en) *	2005-02-28	2006-08-31	Eisai R & D Management Co., Ltd.	Novel combinational use of sulfonamide compound
US20060216288A1 (en) *	2005-03-22	2006-09-28	Amgen Inc	Combinations for the treatment of cancer
CA2604735A1 (en) *	2005-04-12	2006-10-19	Elan Pharma International Limited	Nanoparticulate quinazoline derivative formulations
EP1871347B1 (en)	2005-04-19	2016-08-03	Novartis AG	Pharmaceutical composition
CN101175732B (zh) *	2005-05-12	2010-06-16	黄文林	一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
CN101175734B (zh) *	2005-05-12	2011-10-12	黄文林	一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
WO2006119674A1 (fr) *	2005-05-12	2006-11-16	Wenlin Huang	Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
PT1885187E (pt)	2005-05-13	2013-12-16	Novartis Ag	Métodos para o tratamento de cancro resistente a fármacos
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP1909819A4 (en)	2005-06-17	2010-02-17	Imclone Llc	RECEPTOR ANTAGONISTS FOR THE TREATMENT OF METASTATIC BONE CANCER
CA2652434A1 (en)	2005-07-08	2007-01-18	Xencor, Inc.	Optimized proteins that target ep-cam
SG164368A1 (en) *	2005-07-18	2010-09-29	Bipar Sciences Inc	Treatment of cancer
JP5066446B2 (ja) *	2005-08-01	2012-11-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を予測する方法
EP2281901B1 (en)	2005-08-02	2013-11-27	Eisai R&D Management Co., Ltd.	Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007025044A2 (en)	2005-08-24	2007-03-01	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
CN1300118C (zh) *	2005-08-25	2007-02-14	江苏吴中苏药医药开发有限责任公司	4－(3－氯－4－氟苯基胺基)－7－甲氧基－6－(3－吗啉丙氧基)喹唑啉的制备方法
EP1938842A4 (en) *	2005-09-01	2013-01-09	Eisai R&D Man Co Ltd	METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
ATE488513T1 (de)	2005-09-20	2010-12-15	Astrazeneca Ab	4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
US20070218061A1 (en) *	2005-09-23	2007-09-20	Vasgene Therapeutics, Inc.	Use of ephrinb2 directed agents for the treatment or prevention of viral infections
AU2006311877A1 (en)	2005-11-04	2007-05-18	Wyeth Llc	Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
CA2627598C (en) *	2005-11-07	2013-06-25	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
JP5688877B2 (ja)	2005-11-11	2015-03-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌疾患の治療用キナゾリン誘導体
US9006224B2 (en)	2005-11-21	2015-04-14	Novartis Ag	Neuroendocrine tumor treatment
EP1964837A4 (en) *	2005-11-22	2010-12-22	Eisai R&D Man Co Ltd	Antitumor agent against multiple myeloma
US7977346B2 (en) *	2006-01-17	2011-07-12	Guoqing Paul Chen	Spiro compounds and methods of use
CN101003514A (zh) *	2006-01-20	2007-07-25	上海艾力斯医药科技有限公司	喹唑啉衍生物、其制备方法及用途
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
PE20070978A1 (es) *	2006-02-14	2007-11-15	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
US20070231298A1 (en) *	2006-03-31	2007-10-04	Cell Genesys, Inc.	Cytokine-expressing cancer immunotherapy combinations
AU2007240548A1 (en)	2006-04-05	2007-11-01	Novartis Ag	Combinations of therapeutic agents for treating cancer
US20090233905A1 (en)	2006-04-05	2009-09-17	Gregory Peter Burke	Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
AR060358A1 (es) *	2006-04-06	2008-06-11	Novartis Vaccines & Diagnostic	Quinazolinas para la inhibicion de pdk 1
EP2010521A1 (en)	2006-04-19	2009-01-07	Novartis Ag	Indazole compounds and methods for inhibition of cdc7
PE20080695A1 (es)	2006-04-27	2008-06-28	Banyu Pharma Co Ltd	Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
EP2026800A1 (en)	2006-05-09	2009-02-25	Novartis AG	Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
CA2652442C (en) *	2006-05-18	2014-12-09	Eisai R & D Management Co., Ltd.	Antitumor agent for thyroid cancer
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US20070292883A1 (en) *	2006-06-12	2007-12-20	Ossovskaya Valeria S	Method of treating diseases with PARP inhibitors
EP2044939A1 (en) *	2006-06-29	2009-04-08	Eisai R&D Management Co., Ltd.	Therapeutic agent for liver fibrosis
DK2044084T3 (en)	2006-07-13	2016-05-09	Janssen Pharmaceutica Nv	MTKI-quinazoline derivatives
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20121506A1 (es)	2006-07-14	2012-11-26	Amgen Inc	Compuestos triazolopiridinas como inhibidores de c-met
ME01786B (me)	2006-08-14	2014-09-20	Xencor Inc	Optimizovana antitela usmerena na cd19
KR101472600B1 (ko)	2006-08-28	2014-12-15	에자이 알앤드디 매니지먼트 가부시키가이샤	미분화형 위암에 대한 항종양제
JP2008081492A (ja)	2006-08-31	2008-04-10	Banyu Pharmaceut Co Ltd	オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
AU2007292387A1 (en) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Treatment of cancer
WO2008030891A2 (en) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2008033748A2 (en) *	2006-09-11	2008-03-20	Curis, Inc.	Quinazoline based egfr inhibitors containing a zinc binding moiety
WO2008033782A2 (en)	2006-09-12	2008-03-20	Genentech, Inc.	Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
SI2068880T1 (sl)	2006-09-18	2012-08-31	Boehringer Ingelheim Int	Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
CN101516885A (zh)	2006-09-29	2009-08-26	诺瓦提斯公司	作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
US8883790B2 (en)	2006-10-12	2014-11-11	Astex Therapeutics Limited	Pharmaceutical combinations
EP2073803B1 (en)	2006-10-12	2018-09-19	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008046242A1 (fr) *	2006-10-16	2008-04-24	Institute Of Mataria Medica, Chinese Academy Of Medical Sciences	Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
KR20090091119A (ko) *	2006-10-27	2009-08-26	얀센 파마슈티카 엔.브이.	뇌암을 치료하거나 예방하기 위한 ｍｔ 키나아제 저해제의 용도
BRPI0717753B1 (pt)	2006-10-27	2022-04-12	Bioresponse, Llc	Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
US7851623B2 (en)	2006-11-02	2010-12-14	Astrazeneca Ab	Chemical process
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2125841A1 (en) *	2006-12-13	2009-12-02	Gilead Sciences, Inc.	Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
CA2672438A1 (en)	2006-12-20	2008-07-03	Amgen Inc.	Substituted heterocycles and methods of use
US7977336B2 (en)	2006-12-28	2011-07-12	Banyu Pharmaceutical Co. Ltd	Aminopyrimidine derivatives as PLK1 inhibitors
WO2008086014A2 (en)	2007-01-09	2008-07-17	Amgen Inc.	Bis-aryl amide derivatives useful for the treatment of cancer
WO2008093855A1 (ja)	2007-01-29	2008-08-07	Eisai R & D Management Co., Ltd.	未分化型胃癌治療用組成物
US7998949B2 (en)	2007-02-06	2011-08-16	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2120900A2 (en)	2007-02-15	2009-11-25	Novartis AG	Combination of lbh589 with other therapeutic agents for treating cancer
AU2008219166B2 (en)	2007-02-16	2013-05-16	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
JP2010520225A (ja)	2007-03-02	2010-06-10	ジェネンテック，インコーポレイテッド	低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
WO2008121346A1 (en) *	2007-03-30	2008-10-09	Massachusetts Institute Of Technology	Methods for identifying compounds that modulate neurotrophic factor signaling
AU2008237749B2 (en)	2007-04-16	2013-01-17	Cipla Limited	Process for the preparation of gefitinib
AU2008260498B2 (en)	2007-05-30	2012-11-29	Xencor, Inc.	Methods and compositions for inhibiting CD32b expressing cells
WO2008154249A2 (en)	2007-06-08	2008-12-18	Genentech, Inc.	Gene expression markers of tumor resistance to her2 inhibitor treatment
DK2170827T3 (da) *	2007-06-21	2013-11-18	Janssen Pharmaceutica Nv	Indolin-2-oner og aza-indolin-2-oner
DK2185562T3 (en)	2007-07-27	2016-02-22	Janssen Pharmaceutica Nv	PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
WO2009023185A1 (en) *	2007-08-13	2009-02-19	Vasgene Therapeutics, Inc.	Cancer treatment using humanized antibodies that bind to ephb4
PL2188313T3 (pl)	2007-08-21	2018-04-30	Amgen, Inc.	Białka wiążące ludzki antygen c-fms
JP5474792B2 (ja)	2007-09-10	2014-04-16	キュリス，インコーポレイテッド	亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101861159A (zh) *	2007-10-19	2010-10-13	马尔药品公司	改进的抗肿瘤治疗
EP2211854A4 (en) *	2007-10-19	2011-01-12	Bipar Sciences Inc	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
EP2213673B1 (en)	2007-10-23	2013-06-05	Msd K.K.	Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2220054A2 (en) *	2007-10-29	2010-08-25	Natco Pharma Limited	Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
CA2704000C (en)	2007-11-09	2016-12-13	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
US7732491B2 (en) *	2007-11-12	2010-06-08	Bipar Sciences, Inc.	Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2217244A4 (en) *	2007-11-12	2011-08-31	Bipar Sciences Inc	TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
US20110053991A1 (en) *	2007-11-19	2011-03-03	Gore Lia	Treatment of Histone Deacetylase Mediated Disorders
CL2008003449A1 (es)	2007-11-21	2010-02-19	Imclone Llc	Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
JP2011506343A (ja) *	2007-12-07	2011-03-03	バイパーサイエンシズ，インコーポレイティド	トポイソメラーゼ阻害剤とｐａｒｐ阻害剤との組み合わせによるがんの治療
KR20100093129A (ko)	2007-12-20	2010-08-24	노파르티스 아게	Ｐｉ３ 키나제 억제제로서 사용되는 티아졸 유도체
CN101918374A (zh)	2008-01-18	2010-12-15	纳特科制药有限公司	用于治疗癌症相关病症的6.7-二烷氧基喹唑啉衍生物
JP2011510079A (ja) *	2008-01-22	2011-03-31	コンサートファーマシューティカルズインコーポレイテッド	ゲフィチニブ誘導体
WO2009096377A1 (ja) *	2008-01-29	2009-08-06	Eisai R & D Management Co., Ltd.	血管阻害物質とタキサンとの併用
WO2009095480A1 (en) *	2008-01-30	2009-08-06	Pharma Mar, S.A.	Improved antitumoral treatments
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
MY150290A (en)	2008-02-07	2013-12-31	Boehringer Ingelheim Int	Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
ES2471452T3 (es) *	2008-03-05	2014-06-26	Novartis Ag	Uso de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina para el tratamiento de carcinoma de pulmón de células no pequeñas con resistencia adquirida a los moduladores del receptor del factor de crecimiento epid�rmico (EGFR).
EP2262522A1 (en) *	2008-03-07	2010-12-22	Pharma Mar, S.A.	Improved antitumoral treatments
ES2524259T3 (es)	2008-03-24	2014-12-04	Novartis Ag	Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
CN101544609A (zh)	2008-03-25	2009-09-30	上海艾力斯医药科技有限公司	4-苯胺喹唑啉衍生物的结晶形式
EP2628726A1 (en)	2008-03-26	2013-08-21	Novartis AG	Hydroxamate-based inhibitors of deacetylases b
US8088782B2 (en)	2008-05-13	2012-01-03	Astrazeneca Ab	Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
CA2723984A1 (en)	2008-05-14	2009-11-19	Genomic Health Inc.	Predictors of patient response to treatment with egf receptor inhibitors
CN101584696A (zh)	2008-05-21	2009-11-25	上海艾力斯医药科技有限公司	包含喹唑啉衍生物的组合物及制备方法、用途
NZ616613A (en)	2008-06-17	2015-05-29	Wyeth Llc	Antineoplastic combinations containing hki-272 and vinorelbine
DE102008031040A1 (de)	2008-06-30	2009-12-31	Alexander Priv.-Doz. Dr. Dömling	Iressa zur Anwendung in der Organtransplantation
LT2326329T (lt)	2008-08-04	2017-05-25	Wyeth Llc	4-anilin-3-cianochinolinų ir kapecitabino antinavikiniai deriniai
JP5539351B2 (ja)	2008-08-08	2014-07-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
CN101367793B (zh) *	2008-09-26	2013-09-11	中国科学院广州生物医药与健康研究院	一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
US20110223241A1 (en)	2008-10-16	2011-09-15	Celator Pharmaceuticals, Inc.	Combination methods and compositions
US8710104B2 (en)	2008-11-07	2014-04-29	Triact Therapeutics, Inc.	Catecholic butanes and use thereof for cancer therapy
US8685941B2 (en) *	2008-12-01	2014-04-01	University Of Central Florida Research Foundation, Inc.	Drug composition cytotoxic for pancreatic cancer cells
CN102256941A (zh)	2008-12-18	2011-11-23	诺瓦提斯公司	新的盐
KR20110112352A (ko)	2008-12-18	2011-10-12	노파르티스 아게	1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
JP5627597B2 (ja)	2008-12-18	2014-11-19	ノバルティスアーゲー	１−［４−［１−（４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ）−エチル］−２−エチル−ベンジル］−アゼチジン−３−カルボン酸ヘミフマル酸塩
CN110818633A (zh)	2009-01-16	2020-02-21	埃克塞里艾克西斯公司	一种苹果酸盐及其晶型
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
JP2012516345A (ja)	2009-01-29	2012-07-19	ノバルティスアーゲー	星細胞腫治療用置換ベンゾイミダゾール
JP2012518598A (ja)	2009-02-25	2012-08-16	Ｍｓｄ株式会社	ピリミドピリミドインダゾール誘導体
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8481503B2 (en)	2009-03-06	2013-07-09	Merck Sharp & Dohme Corp.	Combination cancer therapy with an AKT inhibitor and other anticancer agents
WO2010107968A1 (en)	2009-03-18	2010-09-23	Osi Pharmaceuticals, Inc.	Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
CN102356092B (zh)	2009-03-20	2014-11-05	霍夫曼-拉罗奇有限公司	双特异性抗-her抗体
KR20180056796A (ko)	2009-04-06	2018-05-29	와이어쓰 엘엘씨	네라티닙을 이용한 유방암의 치료법
US8530492B2 (en)	2009-04-17	2013-09-10	Nektar Therapeutics	Oligomer-protein tyrosine kinase inhibitor conjugates
AU2010264698C1 (en)	2009-06-26	2013-05-16	Novartis Ag	1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
LT2451445T (lt)	2009-07-06	2019-06-25	Boehringer Ingelheim International Gmbh	Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
US9050341B2 (en) *	2009-07-14	2015-06-09	Natco Pharma Limited	Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2770873A1 (en)	2009-08-12	2011-02-17	Novartis Ag	Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG10201404886PA (en)	2009-08-17	2014-10-30	Intellikine Llc	Heterocyclic compounds and uses thereof
BR112012008061A2 (pt)	2009-08-20	2016-03-01	Novartis Ag	compostos de oxima heterocíclica
BR112012008075A2 (pt)	2009-08-26	2016-03-01	Novartis Ag	compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
BR112012005400A2 (pt)	2009-09-10	2016-04-05	Irm Llc	derivados do tipo éter de heteroarilas bicíclicas
WO2011053779A2 (en)	2009-10-30	2011-05-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
PH12012500823A1 (en)	2009-11-04	2013-01-07	Novartis Ag	Heterocyclic sulfonamide derivatives useful as mek inhibitors
TW201121570A (en)	2009-11-12	2011-07-01	Genentech Inc	A method of promoting dendritic spine density
CA2780875A1 (en)	2009-11-13	2011-05-19	Pangaea Biotech, S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
JP6220126B2 (ja)	2009-11-23	2017-10-25	セルリアン・ファーマ・インコーポレイテッド	治療的送達のためのシクロデキストリンに基づく重合体
JP2013512215A (ja)	2009-11-25	2013-04-11	ノバルティスアーゲー	二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
WO2011069104A2 (en)	2009-12-04	2011-06-09	Genentech, Inc.	Multispecific antibodies, antibody analogs, compositions, and methods
CA2781218A1 (en)	2009-12-08	2011-06-16	Novartis Ag	Heterocyclic sulfonamide derivatives
CU24130B1 (es)	2009-12-22	2015-09-29	Novartis Ag	Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
AR079984A1 (es)	2010-01-12	2012-03-07	Hoffmann La Roche	Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1
WO2011090940A1 (en)	2010-01-19	2011-07-28	Cerulean Pharma Inc.	Cyclodextrin-based polymers for therapeutic delivery
CN102146060B (zh) *	2010-02-09	2013-07-03	陕西师范大学	制备吉非替尼及其中间体的方法
RU2587619C2 (ru)	2010-02-18	2016-06-20	Дженентек, Инк.	Антагонисты неурегулина и применение их в лечении злокачественного новообразования
AU2011222867B2 (en)	2010-03-04	2014-03-06	Annika Algars	Method for selecting patients for treatment with an EGFR inhibitor
WO2011113802A2 (en)	2010-03-17	2011-09-22	F. Hoffmann-La Roche Ag	Imidazopyridine compounds, compositions and methods of use
US20110237686A1 (en)	2010-03-26	2011-09-29	Cerulean Pharma Inc	Formulations and methods of use
CN102971340A (zh)	2010-03-29	2013-03-13	酵活有限公司	具有增强的或抑制的效应子功能的抗体
TWI406853B (zh) *	2010-04-07	2013-09-01	Dev Center Biotechnology	Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
EP2558864A1 (en)	2010-04-16	2013-02-20	Genentech, Inc.	Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
JP2013532149A (ja)	2010-06-17	2013-08-15	ノバルティスアーゲー	ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2011157787A1 (en)	2010-06-17	2011-12-22	Novartis Ag	Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011161217A2 (en)	2010-06-23	2011-12-29	Palacký University in Olomouc	Targeting of vegfr2
CN102958523B (zh)	2010-06-25	2014-11-19	卫材R&D管理有限公司	使用具有激酶抑制作用的组合的抗肿瘤剂
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012031027A1 (en)	2010-08-31	2012-03-08	Genentech, Inc.	Biomarkers and methods of treatment
WO2012035039A1 (en)	2010-09-15	2012-03-22	F. Hoffmann-La Roche Ag	Azabenzothiazole compounds, compositions and methods of use
EP2627648A1 (en)	2010-09-16	2013-08-21	Novartis AG	17aHYDROXYLASE/C17,20-LYASE INHIBITORS
SG188548A1 (en)	2010-09-22	2013-04-30	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2637692A4 (en)	2010-11-12	2014-09-10	Scott & White Healthcare	ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
RU2013126041A (ru)	2010-11-19	2014-12-27	Ф.Хоффманн-Ля Рош Аг	Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2
EP2643351A1 (en)	2010-11-24	2013-10-02	Glaxo Group Limited	Multispecific antigen binding proteins targeting hgf
EA201390917A1 (ru)	2010-12-21	2013-12-30	Новартис Аг	Дигетероарильные соединения в качестве ингибиторов vps34
EP2468883A1 (en)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012085176A1 (en)	2010-12-23	2012-06-28	F. Hoffmann-La Roche Ag	Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
ES2611885T3 (es)	2011-01-31	2017-05-11	Novartis Ag	Derivados heterocíclicos novedosos
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
EP2492688A1 (en)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to antitumor treatment in lung cancer
KR20220031732A (ko)	2011-03-04	2022-03-11	뉴젠 세러퓨틱스 인코포레이티드	알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
JP2014507465A (ja)	2011-03-08	2014-03-27	ノバルティスアーゲー	フルオロフェニル二環式ヘテロアリール化合物
US8609818B2 (en)	2011-03-10	2013-12-17	Omeros Corporation	Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US9321759B2 (en)	2011-03-17	2016-04-26	The Trustees Of The University Of Pennsylvania	Methods and use of bifunctional enzyme-building clamp-shaped molecules
WO2012125904A1 (en)	2011-03-17	2012-09-20	The Trustees Of The University Of Pennsylvania	Mutation mimicking compounds that bind to the kinase domain of egfr
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
WO2012129344A1 (en)	2011-03-23	2012-09-27	Amgen Inc.	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2012144463A1 (ja)	2011-04-18	2012-10-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
EP2702173A1 (en)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
GB201106870D0 (en)	2011-04-26	2011-06-01	Univ Belfast	Marker
KR20140025492A (ko)	2011-04-28	2014-03-04	노파르티스 아게	17α-히드록실라제/C17,20-리아제 억제제
CN102918029B (zh)	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
ES2705950T3 (es)	2011-06-03	2019-03-27	Eisai R&D Man Co Ltd	Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CA2838029A1 (en)	2011-06-09	2012-12-13	Novartis Ag	Heterocyclic sulfonamide derivatives
EP2721008B1 (en)	2011-06-20	2015-04-29	Novartis AG	Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
WO2012175487A1 (en)	2011-06-20	2012-12-27	Novartis Ag	Cyclohexyl isoquinolinone compounds
MX2013015001A (es)	2011-06-27	2014-03-31	Novartis Ag	Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
BR112013030472A2 (pt)	2011-06-30	2019-09-24	Genentech Inc	formulação farmacêutica, artigo de fabricação e método
WO2013007765A1 (en)	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en)	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
AU2012295394B2 (en)	2011-08-12	2016-04-14	Omeros Corporation	Anti-FZD10 monoclonal antibodies and methods for their use
KR20140047160A (ko)	2011-08-12	2014-04-21	에프. 호프만-라 로슈 아게	인다졸 화합물, 조성물 및 사용 방법
US9745288B2 (en)	2011-08-16	2017-08-29	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor
WO2013025853A1 (en)	2011-08-17	2013-02-21	Genentech, Inc.	Neuregulin antibodies and uses thereof
US12194002B2 (en)	2011-08-17	2025-01-14	Dennis Brown	Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
EP2751285B2 (en)	2011-08-31	2020-04-01	Genentech, Inc.	Method for sensitivity testing of a tumour for a egfr kinase inhibitor
CA2848809A1 (en)	2011-09-15	2013-03-21	Novartis Ag	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
JP2014526538A (ja)	2011-09-20	2014-10-06	エフ．ホフマン−ラロシュアーゲー	イミダゾピリジン化合物、組成物及び使用方法
CN103012290B (zh) *	2011-09-28	2015-05-13	齐鲁制药有限公司	一种高纯度吉非替尼的制备方法
MX2014003698A (es)	2011-09-30	2014-07-28	Genentech Inc	Marcadores de diagnostico.
WO2013056069A1 (en)	2011-10-13	2013-04-18	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
CA2853256C (en)	2011-10-28	2019-05-14	Novartis Ag	Novel purine derivatives and their use in the treatment of disease
TWI577671B (zh)	2011-11-14	2017-04-11	Sunshine Lake Pharma Co Ltd	Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103102345B (zh) *	2011-11-14	2015-06-03	广东东阳光药业有限公司	氨基喹唑啉类衍生物及其盐和使用方法
CN103102342B (zh) *	2011-11-14	2014-10-29	广东东阳光药业有限公司	氨基喹唑啉类衍生物及其盐和使用方法
CN104080787B (zh)	2011-11-29	2016-09-14	诺华股份有限公司	吡唑并吡咯烷化合物
EP2785864A2 (en)	2011-11-30	2014-10-08	F. Hoffmann-La Roche AG	Erbb3 mutations in cancer
US9408885B2 (en)	2011-12-01	2016-08-09	Vib Vzw	Combinations of therapeutic agents for treating melanoma
CN103130729B (zh) *	2011-12-05	2015-07-15	齐鲁制药有限公司	一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
CN103172576B (zh) *	2011-12-21	2015-08-05	沈阳药科大学	吉非替尼的苹果酸加成盐及其制备和应用
EP2794594A1 (en)	2011-12-22	2014-10-29	Novartis AG	Quinoline derivatives
IN2014CN04174A (ja)	2011-12-22	2015-09-04	Novartis Ag
US20130178520A1 (en)	2011-12-23	2013-07-11	Duke University	Methods of treatment using arylcyclopropylamine compounds
EA201491264A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355613A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491260A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
JP2015503516A (ja)	2011-12-23	2015-02-02	ノバルティスアーゲー	Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
CA2859867A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
KR20140117644A (ko)	2012-01-31	2014-10-07	스미스클라인 비이참 (코르크) 리미티드	암을 치료하는 방법
EP2822970A1 (en)	2012-03-08	2015-01-14	Halozyme, Inc.	Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013143057A1 (zh)	2012-03-26	2013-10-03	中国科学院福建物质结构研究所	喹唑啉衍生物及用途
EP2831115A1 (en)	2012-03-27	2015-02-04	F. Hoffmann-La Roche AG	Diagnosis and treatments relating to her3 inhibitors
AU2013243097A1 (en)	2012-04-03	2014-10-09	Novartis Ag	Combination products with tyrosine kinase inhibitors and their use
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
JP6381523B2 (ja)	2012-05-16	2018-08-29	ノバルティスアーゲー	Ｐｉ−３キナーゼ阻害剤の投与レジメン
WO2013175417A1 (en)	2012-05-24	2013-11-28	Novartis Ag	Pyrrolopyrrolidinone compounds
KR101457453B1 (ko) *	2012-05-31	2014-11-04	주식회사 종근당	게피티닙의 제조방법 및 이의 제조에 사용되는 중간체
JP6427097B2 (ja)	2012-06-15	2018-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	癌を処置するための組成物および該組成物を製造するための方法
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
WO2014016848A2 (en)	2012-07-24	2014-01-30	Laurus Labs Private Limited	Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
US9738643B2 (en)	2012-08-06	2017-08-22	Duke University	Substituted indazoles for targeting Hsp90
EP2890696A1 (en)	2012-08-29	2015-07-08	Amgen, Inc.	Quinazolinone compounds and derivatives thereof
CA2888803A1 (en)	2012-11-05	2014-05-08	Jooeun Bae	Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
US9334239B2 (en)	2012-12-21	2016-05-10	Eisai R&D Management Co., Ltd.	Amorphous form of quinoline derivative, and method for producing same
CN103073509A (zh) *	2012-12-31	2013-05-01	广东先强药业有限公司	一类喹唑啉衍生物的制备方法
CN103910690A (zh) *	2013-01-06	2014-07-09	上海科胜药物研发有限公司	一种吉非替尼新晶型及其制备方法
ES2651331T3 (es)	2013-01-10	2018-01-25	Glaxosmithkline Intellectual Property (No. 2) Limited	Inhibidores de la sintasa de ácidos grasos
EP2948453B1 (en)	2013-01-22	2017-08-02	Novartis AG	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP2948451B1 (en)	2013-01-22	2017-07-12	Novartis AG	Substituted purinone compounds
MX369611B (es)	2013-02-01	2019-11-14	Wellstat Therapeutics Corp	Compuestos de amina que tienen actividad anti-inflamatoria, antifungica, antiparasitaria y anticancer.
CN111139256A (zh)	2013-02-20	2020-05-12	诺华股份有限公司	使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
EP2958592A1 (en)	2013-02-22	2015-12-30	F. Hoffmann-La Roche AG	Methods of treating cancer and preventing drug resistance
AU2014223548A1 (en)	2013-02-26	2015-10-15	Triact Therapeutics, Inc.	Cancer therapy
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
US9925240B2 (en)	2013-03-06	2018-03-27	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
PE20152000A1 (es)	2013-03-06	2016-01-22	Astrazeneca Ab	Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico
RU2015143517A (ru)	2013-03-13	2017-04-19	Дженентек, Инк.	Пиразолсодержащие соединения и их применения
CA2905993C (en)	2013-03-14	2022-12-06	Tolero Pharmaceuticals, Inc.	Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
EP2968540A2 (en)	2013-03-14	2016-01-20	Genentech, Inc.	Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
EP2968565A2 (en)	2013-03-14	2016-01-20	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
MX2015011899A (es)	2013-03-15	2016-05-05	Genentech Inc	Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
EP2968340A4 (en)	2013-03-15	2016-08-10	Intellikine Llc	COMBINING KINASE INHIBITORS AND USES THEREOF
EP2976085A1 (en)	2013-03-21	2016-01-27	INSERM - Institut National de la Santé et de la Recherche Médicale	Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2014147631A1 (en)	2013-03-22	2014-09-25	Natco Pharma Limited	Formulation comprising gefitinib as oral suspension
WO2014155268A2 (en)	2013-03-25	2014-10-02	Novartis Ag	Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
ES2687968T3 (es)	2013-05-14	2018-10-30	Eisai R&D Management Co., Ltd.	Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
CN103304491A (zh) *	2013-06-17	2013-09-18	连云港盛和生物科技有限公司	一种吉非替尼的制备方法
KR20150001936A (ko) *	2013-06-28	2015-01-07	제일약품주식회사	게피티닙의 신규한 결정형 및 이의 제조방법
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
EP3027623A4 (en) *	2013-08-02	2017-03-01	Ignyta, Inc.	METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
KR20160049003A (ko)	2013-09-05	2016-05-04	제넨테크, 인크.	항증식성 화합물
CA2923667A1 (en)	2013-09-09	2015-03-12	Triact Therapeutics, Inc.	Cancer therapy
BR112016005526A2 (pt)	2013-09-12	2017-09-12	Halozyme Inc	anticorpos receptores de fator de crescimento anti-epidérmido modificado e métodos de uso dos mesmos
SG11201510740YA (en)	2013-09-17	2016-01-28	Obi Pharma Inc	Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
JP6494633B2 (ja)	2013-09-22	2019-04-03	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されているアミノピリミジン化合物および使用方法
CN104513253A (zh) *	2013-10-01	2015-04-15	南京波尔泰药业科技有限公司	用于治疗增殖性疾病的大环化合物
TW201605857A (zh)	2013-10-03	2016-02-16	赫孚孟拉羅股份公司	Ｃｄｋ８之醫療性抑制劑及其用途
US20150147333A1 (en)	2013-10-18	2015-05-28	Genentech, Inc.	Anti-rspo antibodies and methods of use
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
PT3076969T (pt)	2013-12-06	2021-11-23	Novartis Ag	Regime de dosagem de um inibidor de fosfatidilinositol 3- quinase seletivo para a isoforma alfa
RS59659B2 (sr)	2013-12-17	2023-08-31	Hoffmann La Roche	Postupci lečenjа raka pomoću аntаgonistа koji vežu osovinu pd-1 i pomoću tаksаnа
MX2016007965A (es)	2013-12-17	2016-10-28	Genentech Inc	Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015128837A1 (en)	2014-02-26	2015-09-03	Glaxosmithkline Intellectual Property (No.2) Limited	Methods of treating cancer patients responding to ezh2 inhibitor gsk126
CA2943329A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10000469B2 (en)	2014-03-25	2018-06-19	Duke University	Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en)	2014-03-27	2015-10-01	Novartis Ag	Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3122728A4 (en)	2014-03-28	2017-10-25	Calitor Sciences, LLC	Substituted heteroaryl compounds and methods of use
WO2015153514A1 (en)	2014-03-31	2015-10-08	Genentech, Inc.	Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
BR112016022658A2 (pt)	2014-03-31	2017-10-17	Genentech Inc	anticorpos anti-ox40 e métodos de uso
AU2015241198A1 (en)	2014-04-03	2016-11-17	Invictus Oncology Pvt. Ltd.	Supramolecular combinatorial therapeutics
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015170345A1 (en)	2014-05-09	2015-11-12	Council Of Scientific & Industrial Research	Pharmaceutical cocrystals of gefitinib
RU2577518C2 (ru) *	2014-06-02	2016-03-20	Олег Ростиславович Михайлов	КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
WO2015188318A1 (en) *	2014-06-10	2015-12-17	Scinopharm (Changshu) Pharmaceuticals, Ltd.	Process for preparing quinazoline derivative
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
AU2015294889B2 (en)	2014-07-31	2018-03-15	Novartis Ag	Combination therapy
KR102329681B1 (ko)	2014-08-28	2021-11-23	에자이 알앤드디 매니지먼트 가부시키가이샤	고순도의 퀴놀린 유도체 및 이를 제조하는 방법
TWI567063B (zh) *	2014-09-05	2017-01-21	國立交通大學	用於促進癌細胞凋亡的化合物、其醫藥組成物及其用途
CN107074823B (zh)	2014-09-05	2021-05-04	基因泰克公司	治疗性化合物及其用途
CN107073125A (zh)	2014-09-19	2017-08-18	基因泰克公司	Cbp/ep300和bet抑制剂用于治疗癌症的用途
WO2016057924A1 (en)	2014-10-10	2016-04-14	Genentech, Inc.	Pyrrolidine amide compounds as histone demethylase inhibitors
EP3206717B1 (en)	2014-10-17	2020-11-25	Novartis AG	Combination of ceritinib with an egfr inhibitor
AU2015343337A1 (en)	2014-11-03	2017-06-15	Genentech, Inc.	Assays for detecting T cell immune subsets and methods of use thereof
CA2966507A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
SG11201703376QA (en)	2014-11-06	2017-05-30	Genentech Inc	Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016077375A1 (en)	2014-11-10	2016-05-19	Genentech, Inc.	Bromodomain inhibitors and uses thereof
MA40940A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016081384A1 (en)	2014-11-17	2016-05-26	Genentech, Inc.	Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3632915A1 (en)	2014-11-27	2020-04-08	Genentech, Inc.	4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
JP6542799B2 (ja)	2014-12-04	2019-07-10	Ｄｅｌｔａ−ＦｌｙＰｈａｒｍａ株式会社	新規ｐｅｇ誘導体
US20180000827A1 (en)	2014-12-19	2018-01-04	Synthon B.V.	Pharmaceutical composition comprising gefitinib
BR112017010788A2 (pt)	2014-12-23	2017-12-26	Genentech Inc	métodos de identificação de um paciente com câncer e de identificação de um paciente que sofre de câncer que pode beneficiar da administração de um antagonista de vegf, método de tratamento de um paciente com câncer e método para determinar o estágio de câncer de ovário
KR20170095893A (ko)	2014-12-24	2017-08-23	제넨테크, 인크.	방광암에 대한 치료, 진단, 및 예후 방법
EP3240908A2 (en)	2014-12-30	2017-11-08	F. Hoffmann-La Roche AG	Methods and compositions for prognosis and treatment of cancers
NZ734220A (en)	2015-01-06	2022-01-28	Arena Pharm Inc	Methods of treating conditions related to the s1p1 receptor
AU2016205311B2 (en)	2015-01-08	2022-02-17	The Board Of Trustees Of The Leland Stanford Junior University	Factors and cells that provide for induction of bone, bone marrow, and cartilage
JP6889661B2 (ja)	2015-01-09	2021-06-18	ジェネンテック，インコーポレイテッド	４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用
CN107406414B (zh)	2015-01-09	2022-04-19	基因泰克公司	作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
JP6659703B2 (ja)	2015-01-09	2020-03-04	ジェネンテック，インコーポレイテッド	ピリダジノン誘導体および癌の処置におけるそれらの使用
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
KR101635724B1 (ko) *	2015-01-28	2016-07-05	일동제약주식회사	게피티닙의 개선된 제조방법
EP3250571B1 (en)	2015-01-29	2022-11-30	Genentech, Inc.	Therapeutic compounds and uses thereof
CN107438593B (zh)	2015-01-30	2020-10-30	基因泰克公司	治疗化合物及其用途
US20180028662A1 (en)	2015-02-25	2018-02-01	Eisai R&D Management Co., Ltd.	Method for Suppressing Bitterness of Quinoline Derivative
MA41598A (fr)	2015-02-25	2018-01-02	Constellation Pharmaceuticals Inc	Composés thérapeutiques de pyridazine et leurs utilisations
WO2016140717A1 (en)	2015-03-04	2016-09-09	Merck Sharp & Dohme Corp.	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US10231973B2 (en) *	2015-03-20	2019-03-19	Chai Tai Tianqing Pharmaceutical Group Co., Ltd.	Salts of quinazoline derivative and method for preparing the same
JP6955445B2 (ja)	2015-04-07	2021-10-27	ジェネンテック，インコーポレイテッド	アゴニスト性の活性を有する抗原結合複合体及びその使用方法
EP3294770B2 (en)	2015-05-12	2024-03-20	F. Hoffmann-La Roche AG	Therapeutic and diagnostic methods for cancer
EP3708681A1 (en)	2015-05-29	2020-09-16	F. Hoffmann-La Roche AG	Therapeutic and diagnostic methods for cancer
MX2017014740A (es)	2015-06-08	2018-08-15	Genentech Inc	Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
EP3303397A1 (en)	2015-06-08	2018-04-11	H. Hoffnabb-La Roche Ag	Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
US11369623B2 (en)	2015-06-16	2022-06-28	Prism Pharma Co., Ltd.	Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
AU2016280070B2 (en)	2015-06-17	2022-09-15	Genentech, Inc.	Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
KR102603199B1 (ko)	2015-06-22	2023-11-16	아레나 파마슈티칼스, 인크.	Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
EP3795609B1 (en)	2015-07-01	2024-04-03	California Institute of Technology	Cationic mucic acid polymer-based delivery systems
US20180230431A1 (en)	2015-08-07	2018-08-16	Glaxosmithkline Intellectual Property Development Limited	Combination Therapy
KR102587702B1 (ko)	2015-08-20	2023-10-12	에자이 알앤드디 매니지먼트 가부시키가이샤	종양 치료제
JP6946270B2 (ja)	2015-08-26	2021-10-06	ファンダシオンデルセクトルプーブリコエスタタルセントロナショナルデインベスティゲーショネスオンコロジカスカルロス３（エフエスピークニオ）	タンパク質キナーゼ阻害剤としての縮合三環化合物
WO2017041027A1 (en)	2015-09-04	2017-03-09	Obi Pharma, Inc.	Glycan arrays and method of use
EP3347097B1 (en)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
GB201516905D0 (en)	2015-09-24	2015-11-11	Stratified Medical Ltd	Treatment of Neurodegenerative diseases
DK3353210T3 (da)	2015-09-25	2025-01-06	Hoffmann La Roche	Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
CN105250228B (zh) *	2015-10-12	2017-10-24	山东罗欣药业集团股份有限公司	一种吉非替尼的片剂及其原料的制备方法
KR20180073674A (ko)	2015-11-02	2018-07-02	노파르티스 아게	포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
JP2019505476A (ja)	2015-12-01	2019-02-28	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	組合せ処置およびその方法
AU2016369528B2 (en)	2015-12-16	2021-04-22	Genentech, Inc.	Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
EP3397618B1 (en)	2015-12-30	2020-11-18	Synthon B.V.	Process for making crystalline form a of gefitinib
CN105503748A (zh) *	2015-12-31	2016-04-20	哈药集团技术中心	一种吉非替尼的制备方法
CN108368179B (zh)	2016-01-08	2022-08-23	豪夫迈·罗氏有限公司	使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
EP3423596B1 (en)	2016-02-29	2022-09-28	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
EP3436482A4 (en)	2016-03-29	2020-03-11	OBI Pharma, Inc.	ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
WO2017180864A1 (en)	2016-04-14	2017-10-19	Genentech, Inc.	Anti-rspo3 antibodies and methods of use
MX2018012492A (es)	2016-04-15	2019-06-06	Genentech Inc	Métodos para monitorear y tratar el cáncer.
KR20180134347A (ko)	2016-04-15	2018-12-18	제넨테크, 인크.	암의 진단 및 치료 방법
CN109154027A (zh)	2016-04-15	2019-01-04	豪夫迈·罗氏有限公司	用于监测和治疗癌症的方法
WO2017184956A1 (en)	2016-04-22	2017-10-26	Duke University	Compounds and methods for targeting hsp90
CN109379889A (zh)	2016-04-22	2019-02-22	台湾浩鼎生技股份有限公司	通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
US20190151346A1 (en)	2016-05-10	2019-05-23	INSERM (Institute National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
KR101796684B1 (ko) *	2016-05-19	2017-11-10	건국대학교 산학협력단	케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
JP7014736B2 (ja)	2016-05-24	2022-02-01	ジェネンテック，インコーポレイテッド	がんの処置のためのピラゾロピリジン誘導体
JP7160688B2 (ja)	2016-05-24	2022-10-25	ジェネンテック，インコーポレイテッド	Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
CN106045980B (zh) *	2016-06-03	2017-11-03	江苏开放大学	一种喹唑啉衍生物及其制备方法
PT3468997T (pt)	2016-06-08	2023-12-07	Debra Zack	Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b
EP3469099A1 (en)	2016-06-08	2019-04-17	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for cancer
KR20230117482A (ko)	2016-07-27	2023-08-08	오비아이 파머 인코퍼레이티드	면역원성/치료 글리칸 조성물 및 그의 용도
US11643456B2 (en)	2016-07-29	2023-05-09	Obi Pharma, Inc.	Human antibodies, pharmaceutical compositions and methods
US11649289B2 (en)	2016-08-04	2023-05-16	Glaxosmithkline Intellectual Property Development Limited	Anti-ICOS and anti-PD-1 antibody combination therapy
CN109963871A (zh)	2016-08-05	2019-07-02	豪夫迈·罗氏有限公司	具有激动活性的多价及多表位抗体以及使用方法
CN109476748B (zh)	2016-08-08	2023-05-23	豪夫迈·罗氏有限公司	用于癌症的治疗和诊断方法
EP3503914A1 (en)	2016-08-23	2019-07-03	Oncopep, Inc.	Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en)	2016-08-23	2018-03-01	Oncopep, Inc.	Peptide vaccines and durvalumab for treating multiple myeloma
CN106432202B (zh) *	2016-09-22	2019-04-02	郑州大学第一附属医院	喹唑啉类衍生物及其应用
EP3519441B1 (en)	2016-09-27	2022-03-30	Cero Therapeutics, Inc.	Chimeric engulfment receptor molecules
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10207998B2 (en)	2016-09-29	2019-02-19	Duke University	Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US10927083B2 (en)	2016-09-29	2021-02-23	Duke University	Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
AU2017339517B2 (en)	2016-10-06	2024-03-14	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
WO2018078143A1 (en)	2016-10-28	2018-05-03	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
WO2018081648A2 (en)	2016-10-29	2018-05-03	Genentech, Inc.	Anti-mic antibidies and methods of use
AU2017361549B2 (en)	2016-11-21	2023-12-21	Obi Pharma, Inc.	Conjugated biological molecules, pharmaceutical compositions and methods
RS62456B1 (sr)	2016-12-22	2021-11-30	Amgen Inc	Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
AU2018228873A1 (en)	2017-03-01	2019-08-29	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
US9980967B1 (en)	2017-03-16	2018-05-29	National Chiao Tung University	Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
MX2019012187A (es)	2017-04-13	2019-11-25	Hoffmann La Roche	Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
JP2020519576A (ja)	2017-05-16	2020-07-02	エーザイ・アール・アンド・ディー・マネジメント株式会社	肝細胞癌の治療
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
CN111492245A (zh)	2017-07-21	2020-08-04	基因泰克公司	癌症的治疗和诊断方法
CA3070297A1 (en)	2017-08-11	2019-02-14	Genentech, Inc.	Anti-cd8 antibodies and uses thereof
MX2020002502A (es)	2017-09-08	2020-07-20	Amgen Inc	Inhibidores de kras g12c y metodos para utilizarlos.
CA3073073A1 (en)	2017-09-08	2019-03-14	F. Hoffmann-La Roche Ag	Diagnostic and therapeutic methods for cancer
RU2020114641A (ru)	2017-09-26	2021-10-27	Серо Терапьютикс, Инк.	Молекулы химерных интернализационных рецепторов и способы применения
WO2019083960A1 (en)	2017-10-24	2019-05-02	Oncopep, Inc.	PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
US12059463B2 (en)	2017-10-24	2024-08-13	Oncopep, Inc.	Peptide vaccines and pembrolizumab for treating breast cancer
WO2019084395A1 (en)	2017-10-27	2019-05-02	University Of Virginia Patent Foundation	COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
CN109721552B (zh) *	2017-10-30	2022-09-20	上海北卡医药技术有限公司	一种吉非替尼的制备方法
CA3077664A1 (en)	2017-11-06	2019-05-09	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
JP7254076B2 (ja)	2017-11-19	2023-04-07	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	置換ヘテロアリール化合物及び使用方法
CA3085593A1 (en)	2017-12-18	2019-06-27	Sterngreene, Inc.	Pyrimidine compounds useful as tyrosine kinase inhibitors
AU2017444054B2 (en)	2017-12-21	2021-10-07	Hefei Institutes Of Physical Science, Chinese Academy Of Sciences	Class of pyrimidine derivative kinase inhibitors
EP3740468A4 (en)	2018-01-20	2021-10-06	Sunshine Lake Pharma Co., Ltd.	SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
US11708367B2 (en)	2018-01-26	2023-07-25	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
SG11202006921PA (en)	2018-01-26	2020-08-28	Exelixis Inc	Compounds for the treatment of kinase-dependent disorders
US11673897B2 (en)	2018-01-26	2023-06-13	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
AU2019225249A1 (en)	2018-02-26	2020-09-17	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
MX2020010241A (es)	2018-03-28	2020-10-16	Cero Therapeutics Inc	Composiciones de inmunoterapia celular y usos de las mismas.
KR20210024441A (ko)	2018-03-28	2021-03-05	세로 테라퓨틱스, 인코포레이티드	키메라 포식작용 수용체를 위한 발현 벡터, 유전적으로 변형된 숙주 세포, 및 그의 용도
WO2019191334A1 (en)	2018-03-28	2019-10-03	Cero Therapeutics, Inc.	Chimeric tim4 receptors and uses thereof
AU2019247498A1 (en)	2018-04-05	2020-11-26	Sumitomo Pharma Oncology, Inc.	AXL kinase inhibitors and use of the same
MA52501A (fr)	2018-05-04	2021-03-10	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
US11045484B2 (en)	2018-05-04	2021-06-29	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
CN108395410A (zh) *	2018-05-09	2018-08-14	日照市普达医药科技有限公司	一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
CA3100200A1 (en)	2018-05-21	2019-11-28	Nanostring Technologies, Inc.	Molecular gene signatures and methods of using same
EP3802535B1 (en)	2018-06-01	2022-12-14	Amgen, Inc	Kras g12c inhibitors and methods of using the same
BR112020024762A2 (pt)	2018-06-06	2021-03-23	Arena Pharmaceuticals, Inc.	métodos de tratamento de condições relacionadas ao receptor s1p1
AU2019284472B2 (en)	2018-06-11	2024-05-30	Amgen Inc.	KRAS G12C inhibitors for treating cancer
CA3100390A1 (en)	2018-06-12	2020-03-12	Amgen Inc.	Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
US20190381188A1 (en)	2018-06-13	2019-12-19	California Institute Of Technology	Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CN112585166A (zh)	2018-06-23	2021-03-30	豪夫迈·罗氏有限公司	用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
TWI853822B (zh)	2018-06-27	2024-09-01	台灣浩鼎生技股份有限公司	用於糖蛋白工程的糖苷合成酶變體及其使用方法
MX2021000558A (es)	2018-07-18	2021-04-13	Genentech Inc	Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
EP3826988A4 (en)	2018-07-24	2023-03-22	Hygia Pharmaceuticals, LLC	COMPOUNDS, DERIVATIVES AND ANALOGUES FOR CANCER
MX2021000977A (es)	2018-07-26	2021-04-12	Sumitomo Pharma Oncology Inc	Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
WO2020051099A1 (en)	2018-09-03	2020-03-12	Genentech, Inc.	Carboxamide and sulfonamide derivatives useful as tead modulators
KR20210063330A (ko)	2018-09-19	2021-06-01	제넨테크, 인크.	방광암에 대한 치료 및 진단 방법
MX2021003213A (es)	2018-09-21	2021-05-12	Genentech Inc	Metodos de diagnostico para cancer de mama triple negativo.
BR112021006407A8 (pt)	2018-10-04	2022-12-06	Inst Nat Sante Rech Med	uso de inibidores do egfr para ceratodermas
MX2021004348A (es)	2018-10-18	2021-05-28	Genentech Inc	Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7454572B2 (ja)	2018-11-19	2024-03-22	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤及びその使用方法
JP2022515197A (ja)	2018-12-19	2022-02-17	アレイバイオファーマインコーポレイテッド	がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
WO2020131627A1 (en)	2018-12-19	2020-06-25	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
ES2997190T3 (en)	2018-12-20	2025-02-14	Amgen Inc	Heteroaryl amides useful as kif18a inhibitors
KR20210106474A (ko)	2018-12-20	2021-08-30	암젠 인크	Kif18a 억제제
JP2022514268A (ja)	2018-12-20	2022-02-10	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤
JP2022513967A (ja)	2018-12-20	2022-02-09	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
CN113195000A (zh)	2018-12-21	2021-07-30	第一三共株式会社	抗体-药物缀合物和激酶抑制剂的组合
CA3128064A1 (en)	2019-02-01	2020-08-06	Glaxosmithkline Intellectual Property Development Limited	Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
JP2022519649A (ja)	2019-02-08	2022-03-24	ジェネンテック，インコーポレイテッド	がんの診断および治療方法
WO2020172712A1 (en)	2019-02-27	2020-09-03	Epiaxis Therapeutics Pty Ltd	Methods and agents for assessing t-cell function and predicting response to therapy
CA3130695A1 (en)	2019-02-27	2020-09-03	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
KR20210146287A (ko)	2019-03-01	2021-12-03	레볼루션 메디슨즈, 인크.	이환식 헤테로아릴 화합물 및 이의 용도
JP2022522778A (ja)	2019-03-01	2022-04-20	レボリューションメディシンズインコーポレイテッド	二環式ヘテロシクリル化合物及びその使用
WO2020223233A1 (en)	2019-04-30	2020-11-05	Genentech, Inc.	Prognostic and therapeutic methods for colorectal cancer
WO2020226986A2 (en)	2019-05-03	2020-11-12	Genentech, Inc.	Methods of treating cancer with an anti-pd-l1 antibody
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
MX2021014126A (es)	2019-05-21	2022-01-04	Amgen Inc	Formas en estado solido.
US20230295313A1 (en)	2019-06-26	2023-09-21	Glaxosmithkline Intellectual Property Development Limited	Il1rap binding proteins
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
CN114391012A (zh)	2019-08-02	2022-04-22	美国安进公司	作为kif18a抑制剂的吡啶衍生物
JP7640521B2 (ja)	2019-08-02	2025-03-05	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
JP2022542319A (ja)	2019-08-02	2022-09-30	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤
MX2022001295A (es)	2019-08-02	2022-02-22	Amgen Inc	Inhibidores de kif18a.
US20230192853A1 (en)	2019-09-04	2023-06-22	Genentech, Inc.	Cd8 binding agents and uses thereof
WO2021046293A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
WO2021043961A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
US20220315579A1 (en)	2019-09-26	2022-10-06	Exelixis, Inc.	Pyridone compounds and methods of use
PE20221110A1 (es)	2019-09-27	2022-07-11	Genentech Inc	Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
EP4038097A1 (en)	2019-10-03	2022-08-10	Cero Therapeutics, Inc.	Chimeric tim4 receptors and uses thereof
CA3155857A1 (en)	2019-10-24	2021-04-29	Amgen Inc.	Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
US20230024096A1 (en)	2019-10-29	2023-01-26	Hoffmann-La Roche Inc.	Bifunctional compounds for the treatment of cancer
EP4054720A1 (en)	2019-11-04	2022-09-14	Revolution Medicines, Inc.	Ras inhibitors
CN114867735A (zh)	2019-11-04	2022-08-05	锐新医药公司	Ras抑制剂
JP2022553858A (ja)	2019-11-04	2022-12-26	レボリューションメディシンズインコーポレイテッド	Ｒａｓ阻害剤
KR20220092580A (ko)	2019-11-06	2022-07-01	제넨테크, 인크.	혈액암의 치료를 위한 진단과 치료 방법
WO2021092115A1 (en)	2019-11-08	2021-05-14	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
US20210161897A1 (en)	2019-11-12	2021-06-03	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CR20220207A (es)	2019-11-13	2022-06-06	Genentech Inc	Compuestos terapéuticos y métodos de uso
TW202132271A (zh)	2019-11-14	2021-09-01	美商安進公司	Ｋｒａｓｇ１２ｃ抑制劑化合物之改善的合成
AU2020381492A1 (en)	2019-11-14	2022-05-26	Amgen Inc.	Improved synthesis of KRAS G12C inhibitor compound
EP4058465A1 (en)	2019-11-14	2022-09-21	Cohbar Inc.	Cxcr4 antagonist peptides
JP2023505100A (ja)	2019-11-27	2023-02-08	レボリューションメディシンズインコーポレイテッド	共有ｒａｓ阻害剤及びその使用
BR112022011357A2 (pt)	2019-12-13	2022-08-23	Genentech Inc	Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
TW202136276A (zh)	2019-12-20	2021-10-01	美商艾瑞斯卡公司	三環吡啶酮及嘧啶酮
JP2023509701A (ja)	2020-01-07	2023-03-09	レヴォリューション・メディスンズ，インコーポレイテッド	Ｓｈｐ２阻害剤投薬およびがんを処置する方法
US20230056604A1 (en)	2020-01-20	2023-02-23	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021154761A1 (en)	2020-01-27	2021-08-05	Genentech, Inc.	Methods for treatment of cancer with an anti-tigit antagonist antibody
CN115038466A (zh)	2020-01-28	2022-09-09	葛兰素史密斯克莱知识产权发展有限公司	联合治疗及其用途和方法
WO2021177980A1 (en)	2020-03-06	2021-09-10	Genentech, Inc.	Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
WO2021185844A1 (en)	2020-03-16	2021-09-23	Pvac Medical Technologies Ltd	Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en)	2020-05-20	2021-11-25	Pvac Medical Technologies Ltd	Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
CN115380026B (zh) *	2020-03-17	2023-11-07	南京明德新药研发有限公司	蛋白降解调节剂与其使用方法
EP4127724A1 (en)	2020-04-03	2023-02-08	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
EP4143345A1 (en)	2020-04-28	2023-03-08	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
CN118221595A (zh) *	2020-06-15	2024-06-21	山东新时代药业有限公司	一种吉非替尼的有机酸盐
IL299039A (en)	2020-06-16	2023-02-01	Genentech Inc	Methods and preparations for the treatment of triple-negative breast cancer
AU2021293507A1 (en)	2020-06-18	2023-02-02	F. Hoffmann-La Roche Ag	Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
JP2023530351A (ja)	2020-06-18	2023-07-14	レヴォリューション・メディスンズ，インコーポレイテッド	Ｒａｓ阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法
CN115997123A (zh)	2020-06-30	2023-04-21	国家医疗保健研究所	用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
EP4172628A1 (en)	2020-06-30	2023-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
US11787775B2 (en)	2020-07-24	2023-10-17	Genentech, Inc.	Therapeutic compounds and methods of use
EP4189121A1 (en)	2020-08-03	2023-06-07	Genentech, Inc.	Diagnostic and therapeutic methods for lymphoma
US20230285576A1 (en)	2020-08-05	2023-09-14	Ellipses Pharma Ltd	Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
EP4196612A1 (en)	2020-08-12	2023-06-21	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2022036287A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Chimeric tim receptors and uses thereof
WO2022036285A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
IL300930A (en)	2020-08-27	2023-04-01	Enosi Therapeutics Corp	Methods and compositions for the treatment of autoimmune diseases and cancer
WO2022047259A1 (en)	2020-08-28	2022-03-03	California Institute Of Technology	Synthetic mammalian signaling circuits for robust cell population control
CN116209438A (zh)	2020-09-03	2023-06-02	锐新医药公司	使用sos1抑制剂治疗具有shp2突变的恶性疾病
EP4214209A1 (en)	2020-09-15	2023-07-26	Revolution Medicines, Inc.	Indole derivatives as ras inhibitors in the treatment of cancer
WO2022066805A1 (en)	2020-09-23	2022-03-31	Erasca, Inc.	Tricyclic pyridones and pyrimidones
KR20230082632A (ko)	2020-10-05	2023-06-08	제넨테크, 인크.	항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20230107642A1 (en)	2020-12-18	2023-04-06	Erasca, Inc.	Tricyclic pyridones and pyrimidones
TW202241885A (zh)	2020-12-22	2022-11-01	大陸商上海齊魯銳格醫藥研發有限公司	Ｓｏｓ１抑制劑及其用途
CN112321814B (zh) *	2020-12-30	2021-03-23	广州初曲科技有限公司	一种吉非替尼艾地苯醌轭合物的制备及用途
KR20230146052A (ko)	2021-02-12	2023-10-18	에프. 호프만-라 로슈 아게	암 치료용 비시클릭 테트라히드로아제핀 유도체
WO2022178205A1 (en)	2021-02-19	2022-08-25	Exelixis, Inc.	Pyridone compounds and methods of use
CN117203223A (zh)	2021-02-26	2023-12-08	凯洛尼亚疗法有限公司	淋巴细胞靶向慢病毒载体
CN117500811A (zh)	2021-05-05	2024-02-02	锐新医药公司	共价ras抑制剂及其用途
AR125787A1 (es)	2021-05-05	2023-08-16	Revolution Medicines Inc	Inhibidores de ras
JP2024517847A (ja)	2021-05-05	2024-04-23	レボリューションメディシンズインコーポレイテッド	Ｒａｓ阻害剤
JP2024520457A (ja)	2021-05-25	2024-05-24	エラスカ・インコーポレイテッド	硫黄含有ヘテロ芳香族三環式ｋｒａｓ阻害剤
WO2022266206A1 (en)	2021-06-16	2022-12-22	Erasca, Inc.	Kras inhibitor conjugates
CN113527266A (zh) *	2021-06-23	2021-10-22	上海健康医学院	一种靶向fap的双氧水响应的前药及其制备方法与应用
CN113336742B (zh)	2021-06-29	2022-05-10	山东金吉利新材料有限公司	一种马来酸吡咯替尼中间体的合成方法
AU2022315530A1 (en)	2021-07-20	2024-01-18	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their preparation, and uses
JP2024529474A (ja)	2021-07-28	2024-08-06	セロ・セラピューティクス・インコーポレイテッド	キメラＴｉｍ４受容体およびその使用
WO2023018699A1 (en)	2021-08-10	2023-02-16	Erasca, Inc.	Selective kras inhibitors
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
CN113845485B (zh) *	2021-10-22	2023-03-14	湖南中医药大学	氨基酸衍生物及其制备方法和应用
TW202332429A (zh)	2021-11-24	2023-08-16	美商建南德克公司	治療性化合物及其使用方法
TW202340212A (zh)	2021-11-24	2023-10-16	美商建南德克公司	治療性化合物及其使用方法
EP4448526A1 (en)	2021-12-17	2024-10-23	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023144127A1 (en)	2022-01-31	2023-08-03	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
CN119136806A (zh)	2022-03-08	2024-12-13	锐新医药公司	用于治疗免疫难治性肺癌的方法
AU2023246862A1 (en)	2022-03-31	2024-10-31	Astrazeneca Ab	Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
CN119487067A (zh)	2022-04-01	2025-02-18	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
EP4522653A1 (en)	2022-05-11	2025-03-19	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL317449A (en)	2022-06-07	2025-02-01	Genentech Inc	Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
KR20250029133A (ko)	2022-06-27	2025-03-04	아스트라제네카 아베	암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
TW202417042A (zh)	2022-07-13	2024-05-01	美商建南德克公司	用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
CN119604530A (zh)	2022-07-19	2025-03-11	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
AU2023317584A1 (en)	2022-08-02	2025-02-13	Luca Science Inc.	Methods of improving cellular therapy with organelle complexes
AR130167A1 (es)	2022-08-11	2024-11-13	Hoffmann La Roche	Derivados bicíclicos de tetrahidroazepina
TW202417439A (zh)	2022-08-11	2024-05-01	瑞士商赫孚孟拉羅股份公司	雙環四氫噻吖呯衍生物
IL316935A (en)	2022-08-11	2025-01-01	Hoffmann La Roche	TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES
CN119698413A (zh)	2022-08-11	2025-03-25	豪夫迈·罗氏有限公司	双环四氢硫氮杂䓬衍生物
WO2024081916A1 (en)	2022-10-14	2024-04-18	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024085242A2 (en)	2022-10-21	2024-04-25	Kawasaki Institute Of Industrial Promotion	Non-fouling or super stealth vesicle
WO2024088808A1 (en)	2022-10-24	2024-05-02	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024091991A1 (en)	2022-10-25	2024-05-02	Genentech, Inc.	Therapeutic and diagnostic methods for multiple myeloma
TW202434206A (zh)	2023-02-17	2024-09-01	美商伊瑞斯卡公司	Ｋｒａｓ抑制劑
WO2024206858A1 (en)	2023-03-30	2024-10-03	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en)	2023-04-14	2024-10-24	Revolution Medicines, Inc.	Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202446388A (zh)	2023-04-14	2024-12-01	美商銳新醫藥公司	Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
WO2024233341A1 (en)	2023-05-05	2024-11-14	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024254455A1 (en)	2023-06-08	2024-12-12	Genentech, Inc.	Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025024257A1 (en)	2023-07-21	2025-01-30	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025049277A1 (en)	2023-08-25	2025-03-06	Genentech, Inc.	Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3266990A (en) *	1963-09-24	1966-08-16	Warner Lambert Pharmaceutical	Derivatives of quinazoline
JPS5538325A (en) *	1978-09-11	1980-03-17	Sankyo Co Ltd	4-anilinoquinazoline derivative and its preparation
US4343940A (en) *	1979-02-13	1982-08-10	Mead Johnson & Company	Anti-tumor quinazoline compounds
GB2160201B (en) *	1984-06-14	1988-05-11	Wyeth John & Brother Ltd	Quinazoline and cinnoline derivatives
DE68917485T2 (de) *	1988-01-23	1995-02-09	Kyowa Hakko Kogyo Kk	Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen.
IL89029A (en) *	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
AU655798B2 (en) *	1991-02-20	1995-01-12	Pfizer Inc.	2,4-diaminoquinazolines derivatives for enhancing antitumor activity
US5721237A (en) *	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
ES2108120T3 (es) *	1991-05-10	1997-12-16	Rhone Poulenc Rorer Int	Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) *	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) *	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314893D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
US5661147A (en) *	1993-09-03	1997-08-26	Kyowa Hakko Kogyo Co., Ltd.	Imidazoquinazoline derivatives
US5409000A (en) *	1993-09-14	1995-04-25	Cardiac Pathways Corporation	Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method
GB9325217D0 (en) *	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
PL315941A1 (en) *	1994-02-23	1996-12-09	Pfizer	4-heterocyclic substituted derivatives of quinazoline, methods of obtaining them and their application as anticarcinogenic agents
AU2096895A (en) *	1994-03-07	1995-09-25	Sugen, Incorporated	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (ja) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
WO1996029331A1 (de) *	1995-03-20	1996-09-26	Dr. Karl Thomae Gmbh	Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE19510019A1 (de) *	1995-03-20	1996-09-26	Thomae Gmbh Dr K	Imidazo[4,5-g]chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE69536015D1 (de) *	1995-03-30	2009-12-10	Pfizer Prod Inc	Chinazolinone Derivate
NZ304859A (en) *	1995-04-03	2000-01-28	Novartis Ag	4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives, medicaments and processes for the preparation thereof
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
JPH11507329A (ja) *	1995-04-27	1999-06-29	ゼネカリミテッド	キナゾリン誘導体
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
IL117923A (en) *	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
DE69603240T2 (de) *	1995-05-12	2000-01-05	Neurogen Corp., Branford	Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
DK0831829T3 (da) *	1995-06-07	2003-12-15	Pfizer	Heterocykliske, ringkondenserede pyrimidinderivater
AU5984296A (en) *	1995-06-07	1996-12-30	Sugen, Inc.	Quinazolines and pharmaceutical compositions
DE69619114T2 (de) *	1995-07-06	2002-10-02	Novartis Ag, Basel	Pyrolopyrimidine und verfahren zu ihrer herstellung
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
AR004010A1 (es) *	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9520822D0 (en) *	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds

1995
- 1995-04-27 GB GBGB9508538.7A patent/GB9508538D0/en active Pending
1996
- 1996-04-08 TW TW085104049A patent/TW436486B/zh not_active IP Right Cessation
- 1996-04-23 NZ NZ305444A patent/NZ305444A/xx not_active IP Right Cessation
- 1996-04-23 DK DK96910134T patent/DK0823900T3/da active
- 1996-04-23 CZ CZ19973396A patent/CZ288489B6/cs not_active IP Right Cessation
- 1996-04-23 PL PL96323066A patent/PL189182B1/pl unknown
- 1996-04-23 CN CN96193526A patent/CN1100046C/zh not_active Expired - Lifetime
- 1996-04-23 HU HU9802839A patent/HU223313B1/hu active Protection Beyond IP Right Term
- 1996-04-23 PT PT96910134T patent/PT823900E/pt unknown
- 1996-04-23 SI SI9630183T patent/SI0823900T1/xx unknown
- 1996-04-23 EE EE9700252A patent/EE03482B1/xx active Protection Beyond IP Right Term
- 1996-04-23 EG EG35896A patent/EG24134A/xx active
- 1996-04-23 CA CA002215732A patent/CA2215732C/en not_active Expired - Lifetime
- 1996-04-23 RU RU97119521/04A patent/RU2153495C2/ru active Protection Beyond IP Right Term
- 1996-04-23 DE DE69611361T patent/DE69611361T2/de not_active Expired - Lifetime
- 1996-04-23 DE DE122009000076C patent/DE122009000076I1/de active Pending
- 1996-04-23 WO PCT/GB1996/000961 patent/WO1996033980A1/en active IP Right Grant
- 1996-04-23 JP JP8532252A patent/JP3040486B2/ja not_active Expired - Lifetime
- 1996-04-23 EP EP96910134A patent/EP0823900B1/en not_active Expired - Lifetime
- 1996-04-23 KR KR1019970707511A patent/KR100296656B1/ko not_active IP Right Cessation
- 1996-04-23 AT AT96910134T patent/ATE198329T1/de active
- 1996-04-23 AU AU53433/96A patent/AU699163B2/en not_active Expired
- 1996-04-23 UA UA97115677A patent/UA52602C2/uk unknown
- 1996-04-23 SK SK1454-97A patent/SK282236B6/sk not_active IP Right Cessation
- 1996-04-23 BR BRPI9608082A patent/BRPI9608082B8/pt not_active IP Right Cessation
- 1996-04-23 RO RO97-01978A patent/RO117849B1/ro unknown
- 1996-04-23 ES ES96910134T patent/ES2153098T3/es not_active Expired - Lifetime
- 1996-04-24 AR ARP960102305A patent/AR003944A1/es unknown
- 1996-04-25 HR HR960204A patent/HRP960204B1/xx not_active IP Right Cessation
- 1996-04-25 MY MYPI96001577A patent/MY114425A/en unknown
- 1996-04-26 ZA ZA963358A patent/ZA963358B/xx unknown
- 1996-04-26 US US08/638,331 patent/US5770599A/en not_active Expired - Lifetime
- 1996-04-26 IL IL11804596A patent/IL118045A/en active Protection Beyond IP Right Term
1997
- 1997-10-24 NO NO974940A patent/NO309472B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102052A patent/BG62730B1/bg unknown
1998
- 1998-05-25 HK HK98104504A patent/HK1005371A1/xx not_active IP Right Cessation
2001
- 2001-01-11 GR GR20010400025T patent/GR3035211T3/el unknown
2009
- 2009-12-15 FR FR09C0065C patent/FR09C0065I2/fr active Active
- 2009-12-16 NO NO2009028C patent/NO2009028I1/no unknown
- 2009-12-17 NL NL300429C patent/NL300429I1/nl unknown
- 2009-12-17 LU LU91631C patent/LU91631I2/fr unknown

Also Published As

Publication number	Publication date
TW436486B (en)	2001-05-28
IL118045A0 (en)	1996-08-04
CA2215732C (en)	2002-04-09
BRPI9608082B8 (pt)	2021-07-06
EP0823900B1 (en)	2000-12-27
PL323066A1 (en)	1998-03-02
KR100296656B1 (ko)	2001-08-07
AU699163B2 (en)	1998-11-26
GB9508538D0 (en)	1995-06-14
CA2215732A1 (en)	1996-10-31
NZ305444A (en)	1999-03-29
CZ339697A3 (cs)	1998-02-18
DE69611361T2 (de)	2001-04-26
LU91631I2 (fr)	2010-02-17
RO117849B1 (ro)	2002-08-30
JP3040486B2 (ja)	2000-05-15
NO2009028I2 (no)	2011-10-17
HUP9802839A2 (hu)	1999-03-29
GR3035211T3 (en)	2001-04-30
EE9700252A (et)	1998-04-15
RU2153495C2 (ru)	2000-07-27
FR09C0065I2 (fr)	2014-03-28
BRPI9608082B1 (pt)	2019-04-30
IL118045A (en)	2001-10-31
NL300429I1 (nl)	2010-03-01
ATE198329T1 (de)	2001-01-15
NO974940D0 (no)	1997-10-24
CN1182421A (zh)	1998-05-20
BRPI9608082A (pt)	1999-01-26
HRP960204B1 (en)	2001-10-31
PT823900E (pt)	2001-04-30
US5770599A (en)	1998-06-23
NO2009028I1 (no)	2014-05-19
BG102052A (en)	1998-08-31
BG62730B1 (bg)	2000-06-30
WO1996033980A1 (en)	1996-10-31
EE03482B1 (et)	2001-08-15
HUP9802839A3 (en)	2001-02-28
JPH11504033A (ja)	1999-04-06
DK0823900T3 (da)	2001-04-02
ZA963358B (en)	1996-10-28
UA52602C2 (uk)	2003-01-15
KR19990007987A (ko)	1999-01-25
PL189182B1 (pl)	2005-07-29
CZ288489B6 (en)	2001-06-13
EP0823900A1 (en)	1998-02-18
DE69611361D1 (de)	2001-02-01
CN1100046C (zh)	2003-01-29
HRP960204A2 (en)	1997-08-31
MY114425A (en)	2002-10-31
AU5343396A (en)	1996-11-18
SI0823900T1 (ja)	2001-06-30
ES2153098T3 (es)	2001-02-16
EG24134A (en)	2008-08-06
HU223313B1 (hu)	2004-05-28
DE122009000076I1 (de)	2010-05-06
HK1005371A1 (en)	1999-01-08
AR003944A1 (es)	1998-09-30
NO309472B1 (no)	2001-02-05
SK145497A3 (en)	1998-02-04
NO974940L (no)	1997-10-24
SK282236B6 (sk)	2001-12-03

Publication	Publication Date	Title
DE69638352D1 (ja)	2011-05-19
DE69637714D1 (ja)	2008-11-27
FR09C0065I1 (ja)	2010-01-22
BR122012014331A2 (ja)	1999-01-05
BRPI9612258B1 (ja)	2011-05-31
BRPI9612138B1 (ja)	2009-09-22
IN186362B (ja)	2001-08-18
DK143195A (ja)	1997-05-04
CH0741373H1 (ja)	2011-10-14
DK0727898T3 (ja)	1997-03-17
DK126096A (ja)	1996-11-08
BR7502120U (ja)	1998-04-14
BR7501503U (ja)	1997-11-25
CN3032568S (ja)	1995-06-14
CN3034829S (ja)	1995-09-06
CN3031001S (ja)	1995-03-29
CN3031350S (ja)	1995-04-19
CN3031655S (ja)	1995-05-10
CN3031742S (ja)	1995-05-10
CN3031926S (ja)	1995-05-17
CN3036648S (ja)	1995-10-25
CN3032390S (ja)	1995-06-07
CN3032522S (ja)	1995-06-07
CN3037560S (ja)	1995-11-22
CN3032692S (ja)	1995-06-14